Related Experiment Video

Updated: Jun 28, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Current and future anti-fibrotic therapies for chronic liver disease

Don C Rockey1

  • 1Division of Digestive and Liver Diseases, Department of Internal Medicine, The University of Texas, Southwestern Medical Center, Dallas, TX 75390, USA. don.rockey@utsouthwestern.edu

Clinics in Liver Disease
|November 6, 2008
PubMed

Insights

Chronic liver injury leads to fibrosis, a common but untreatable condition. Understanding fibrogenesis mechanisms offers hope for novel antifibrotic therapies to combat liver scarring.

Area of Science:

  • Hepatology
  • Fibrosis Research
  • Wound Healing Biology

Background:

  • Chronic injury triggers a generalized wound healing response culminating in fibrosis across organ systems.
  • Liver injury from diverse causes initiates fibrogenesis, suggesting a shared underlying pathogenesis.
  • Despite advances in treating specific liver diseases, effective antifibrotic therapies remain unavailable.

Purpose of the Study:

  • To review the mechanisms driving hepatic fibrogenesis.
  • To explore potential and existing antifibrotic therapeutic strategies.

Main Methods:

  • Review of recent scientific literature on liver fibrosis.
  • Analysis of molecular and cellular pathways involved in hepatic fibrogenesis.
  • Evaluation of preclinical and clinical data on antifibrotic agents.

Main Results:

  • Significant progress has been made in understanding the complex mechanisms of liver fibrosis over the past two decades.
  • Multiple pathways contributing to hepatic fibrogenesis have been identified.
  • Preclinical studies suggest several promising therapeutic targets for abrogating fibrosis.

Conclusions:

  • Elucidating fibrogenesis mechanisms is crucial for developing effective antifibrotic treatments.
  • Novel therapeutic strategies targeting identified pathways show potential for treating liver fibrosis.
  • Further research and clinical trials are needed to translate these findings into effective patient therapies.

More Related Videos

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...